Hosted on MSN5h
AstraZeneca’s diabetes drug fails to slow Parkinson’s progression in UCL trial
Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...
Hosted on MSN7h
Supernus wins FDA approval for Parkinson’s pump on fourth try
Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of ...
FDA approves wearable infusion device for advanced Parkinson disease
The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...
It’s not just forgetfulness: 8 early warning signs of dementia
One of the most common early signs of dementia is short-term memory loss—as is forgetting important dates or events, ...
Frontiers16d
Recent advances in nanotechnology for Parkinson’s disease: diagnosis, treatment, and future perspectives
Parkinson’s disease is a progressive neurodegenerative disease that destroys substantia nigra dopaminergic neurons, causing tremors, bradykinesia, rigidity, and postural instability. Current treatment ...
Phys.org22d
Nanoparticles restore neurons in Parkinson's with wireless brain stimulation
Get Instant Summarized Text (Gist) A wireless photothermal deep brain stimulation (DBS) nanosystem, ATB NPs, has been developed to treat Parkinson's disease by targeting dopaminergic neurons. This ...
Harvard Medical School22d
New Understanding of How Genetic Mutation Causes Huntington’s Disease
Video: Broad Institute of MIT and Harvard At a glance: Study explains long-standing question of why Huntington’s disease symptoms typically do not appear until midlife even though patients are born ...
Medical Xpress24d
Vascular Disease
People living with atopic dermatitis (AD, also known as eczema) are also at significantly higher risk for peripheral vascular disease ... of dementia and Parkinson's disease, according to a ...
Healio24d
Allosteric modulator nonsuperior to placebo in Parkinson’s disease
those given placebo. Treatment with an oral allosteric modulator was nonsuperior to placebo at 6 weeks in adults with Parkinson’s disease whose symptoms included fall risk and cognitive issues ...